DDO-5936

Modify Date: 2024-01-11 19:02:16

Use of DDO-5936

DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer[1].

Name	DDO-5936
Synonym	More Synonyms

Description	DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> HSP Signaling Pathways >> Cell Cycle/DNA Damage >> HSP
Target	Hsp90-Cdc37 PPI[1]
In Vitro	DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47[1].
In Vivo	DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group[1]. DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency[1]. Animal Model: Mice[1] Dosage: 0~80 mg/kg Administration: P.o. Result: Showed a moderate effect at the high dose group.
References	[1]. Wang L, et al. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. J Med Chem. 2020;63(3):1281-1297.

Glycine, N-[4-[[2-(1-pyrrolidinyl)-4-pyrimidinyl]amino]phenyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]-

Get all suppliers and price by the below link: